Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

Name: Ward: NHI: Epoetin beta INITIATION – chronic renal failure Prerequisites (tick boxes where appropriate) Patient in chronic renal failure Haemoglobin is less than or equal to 100g/L and Haemoglobin is less than or equal to 100g/L				
INITIATION – chronic renal failure Prerequisites (tick boxes where appropriate) Patient in chronic renal failure and Haemoglobin is less than or equal to 100g/L				
INITIATION – chronic renal failure Prerequisites (tick boxes where appropriate) O Patient in chronic renal failure and Haemoglobin is less than or equal to 100g/L and				
Prerequisites (tick boxes where appropriate) O Patient in chronic renal failure and Haemoglobin is less than or equal to 100g/L and				
And Haemoglobin is less than or equal to 100g/L and				
Haemoglobin is less than or equal to 100g/L				
Patient does not have diabetes mellitus and Glomerular filtration rate is less than or equal to 30ml/min				
O Patient has diabetes mellitus				
Glomerular filtration rate is less than or equal to 45ml/min				
O Patient is on haemodialysis or peritoneal dialysis				
INITIATION – myelodysplasia* Re-assessment required after 12 months Prerequisites (tick boxes where appropriate)				
O Patient has a confirmed diagnosis of myelodysplasia (MDS) and				
Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent and				
Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplasyndrome (WPSS) and	ıstic			
Other causes of anaemia such as B12 and folate deficiency have been excluded				
Patient has a serum epoetin level of < 500 IU/L				
The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week				
CONTINUATION – myelodysplasia* Re-assessment required after 2 months Prerequisites (tick boxes where appropriate)				
The patient's transfusion requirement continues to be reduced with epoetin treatment				
Transformation to acute myeloid leukaemia has not occurred and				
The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week	J			

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRES	CRIBER		PATIENT:		
Name	e:		Name:		
Ward	:		NHI:		
Epoetin beta - continued					
INITIATION – all other indications					
Prer	equisites	(tick boxes where appropriate)			
	O	Haematologist			
	_	For use in patients where blood transfusion is not a viable treat	atment alternative		
	and	*Note: Indications marked with * are unapproved indications			

Signed: Date: